Machine Learning for Targeted Nano Medicine in Parkinson's Disease: A Data-Driven Approach for Diagnosis and Treatment.

IF 3.6 4区 医学 Q3 CHEMISTRY, MEDICINAL
Rachit Manchanda, Hardik Doshi, M M Rekha, G Nancy Priscilla, Rajashree Panigrahi, Jayant Jagtap, Abhijit Bhowmik, Rupesh Gupta, Jigna Prajapati, Biswajit Basu
{"title":"Machine Learning for Targeted Nano Medicine in Parkinson's Disease: A Data-Driven Approach for Diagnosis and Treatment.","authors":"Rachit Manchanda, Hardik Doshi, M M Rekha, G Nancy Priscilla, Rajashree Panigrahi, Jayant Jagtap, Abhijit Bhowmik, Rupesh Gupta, Jigna Prajapati, Biswajit Basu","doi":"10.2174/0115680266418706260310070233","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Parkinson's Disease (PD) is a progressive neurodegenerative disorder that impairs motor and cognitive functioning, making early diagnosis and patient-specific treatment essential; however, traditional clinical assessments often delay detection and lack consistency.</p><p><strong>Methods: </strong>This paper proposes TriFusion-PD, a multimodal Machine-Learning-Driven Targeted Nanomedicine (ML-TN) framework designed to improve early PD diagnosis and personalized therapy. The methodology integrates Transformers for analyzing temporal voice and speech patterns, Convolutional Neural Networks (CNNs) for extracting spatial biomarkers from MRI and spiral-drawing images, and Reinforcement Learning (RL) for optimizing individualized treatment recommendations. Three publicly available datasets-voice recordings, speech-signal features, and drawing/imaging data-were pre-processed, feature-engineered, and evaluated through a unified ML pipeline using metrics such as accuracy, precision, recall, F1-score, Matthews Correlation Coefficient (MCC), robustness, computational efficiency, and ROC-AUC.</p><p><strong>Results: </strong>The findings show that TriFusion-PD significantly outperforms baseline models including CNN, SVM-KNN, XGBoost, LSTM, and Random Forest, achieving up to 12.5% higher accuracy, 14.2% higher precision, 15.0% higher recall, and 13.8% higher F1-score, with the highest improvement observed in MCC (16.4%), indicating more balanced and reliable PD classification across modalities.</p><p><strong>Discussion: </strong>These performance gains arise from the complementary strengths of multimodal fusion, which enhances sensitivity to subtle PD symptoms, while RL-based optimization reduces misclassification and improves predictive stability under noisy or incomplete data conditions.</p><p><strong>Conclusion: </strong>Overall, TriFusion-PD presents a robust and clinically relevant data-driven solution for early PD detection and personalized treatment planning, demonstrating strong potential for integration into next-generation clinical decision-support systems.</p>","PeriodicalId":11076,"journal":{"name":"Current topics in medicinal chemistry","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2026-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current topics in medicinal chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115680266418706260310070233","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Parkinson's Disease (PD) is a progressive neurodegenerative disorder that impairs motor and cognitive functioning, making early diagnosis and patient-specific treatment essential; however, traditional clinical assessments often delay detection and lack consistency.

Methods: This paper proposes TriFusion-PD, a multimodal Machine-Learning-Driven Targeted Nanomedicine (ML-TN) framework designed to improve early PD diagnosis and personalized therapy. The methodology integrates Transformers for analyzing temporal voice and speech patterns, Convolutional Neural Networks (CNNs) for extracting spatial biomarkers from MRI and spiral-drawing images, and Reinforcement Learning (RL) for optimizing individualized treatment recommendations. Three publicly available datasets-voice recordings, speech-signal features, and drawing/imaging data-were pre-processed, feature-engineered, and evaluated through a unified ML pipeline using metrics such as accuracy, precision, recall, F1-score, Matthews Correlation Coefficient (MCC), robustness, computational efficiency, and ROC-AUC.

Results: The findings show that TriFusion-PD significantly outperforms baseline models including CNN, SVM-KNN, XGBoost, LSTM, and Random Forest, achieving up to 12.5% higher accuracy, 14.2% higher precision, 15.0% higher recall, and 13.8% higher F1-score, with the highest improvement observed in MCC (16.4%), indicating more balanced and reliable PD classification across modalities.

Discussion: These performance gains arise from the complementary strengths of multimodal fusion, which enhances sensitivity to subtle PD symptoms, while RL-based optimization reduces misclassification and improves predictive stability under noisy or incomplete data conditions.

Conclusion: Overall, TriFusion-PD presents a robust and clinically relevant data-driven solution for early PD detection and personalized treatment planning, demonstrating strong potential for integration into next-generation clinical decision-support systems.

机器学习靶向纳米药物治疗帕金森病:一种数据驱动的诊断和治疗方法。
简介:帕金森病(PD)是一种进行性神经退行性疾病,损害运动和认知功能,早期诊断和患者特异性治疗至关重要;然而,传统的临床评估往往延迟检测和缺乏一致性。方法:本文提出了triffusion -PD,这是一个多模式机器学习驱动的靶向纳米医学(ML-TN)框架,旨在提高PD的早期诊断和个性化治疗。该方法集成了用于分析时间语音和语音模式的transformer,用于从MRI和螺旋绘制图像中提取空间生物标志物的卷积神经网络(cnn),以及用于优化个性化治疗建议的强化学习(RL)。三个公开可用的数据集-录音,语音信号特征和绘图/成像数据-通过统一的ML管道进行预处理,特征工程和评估,使用诸如准确性,精度,召回率,f1分数,马修斯相关系数(MCC),鲁棒性,计算效率和ROC-AUC等指标。结果:研究结果表明,triffusion -PD显著优于基线模型,包括CNN、SVM-KNN、XGBoost、LSTM和Random Forest,准确率提高12.5%,精度提高14.2%,召回率提高15.0%,f1评分提高13.8%,其中MCC的改进幅度最大(16.4%),表明跨模式的PD分类更加平衡和可靠。讨论:这些性能提升来自多模态融合的互补优势,它增强了对细微PD症状的敏感性,而基于rl的优化减少了误分类,提高了在嘈杂或不完整数据条件下的预测稳定性。结论:总的来说,triffusion -PD为早期PD检测和个性化治疗计划提供了一个强大的、临床相关的数据驱动解决方案,显示出整合到下一代临床决策支持系统的强大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.40
自引率
2.90%
发文量
186
审稿时长
3-8 weeks
期刊介绍: Current Topics in Medicinal Chemistry is a forum for the review of areas of keen and topical interest to medicinal chemists and others in the allied disciplines. Each issue is solely devoted to a specific topic, containing six to nine reviews, which provide the reader a comprehensive survey of that area. A Guest Editor who is an expert in the topic under review, will assemble each issue. The scope of Current Topics in Medicinal Chemistry will cover all areas of medicinal chemistry, including current developments in rational drug design, synthetic chemistry, bioorganic chemistry, high-throughput screening, combinatorial chemistry, compound diversity measurements, drug absorption, drug distribution, metabolism, new and emerging drug targets, natural products, pharmacogenomics, and structure-activity relationships. Medicinal chemistry is a rapidly maturing discipline. The study of how structure and function are related is absolutely essential to understanding the molecular basis of life. Current Topics in Medicinal Chemistry aims to contribute to the growth of scientific knowledge and insight, and facilitate the discovery and development of new therapeutic agents to treat debilitating human disorders. The journal is essential for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important advances.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书